Hemostemix Submits its Retrospective Heart Study to Leading Stem Cell Journal and has Prepared its CLI Phase II Clinical Trial Manuscript for Peer Review Read More
Hemostemix’s Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to Biocardia’s Cardiamp Heart Failure Trial Read More
Hemostemix’s VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments! Read More
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01 Read More
Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants Read More
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval Read More
